FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295226681> ?p ?o ?g. }

• W4295226681 endingPage "S66" @default.
• W4295226681 startingPage "S66" @default.
• W4295226681 abstract "Objectives: Response rates to immune checkpoint inhibitors (ICI) in recurrent ovarian cancer have been disappointingly low. While emerging data suggest increased activity in patients with ovarian clear cell carcinomas (OCCC), only a minority of patients benefit even among this group. The objective of the current study was to investigate correlates of long-term survival in patients with OCCC treated with ICI. Methods: A review of medical records identified 28 patients with ovarian/peritoneal clear cell carcinoma who had been treated with CTLA4 and PD1/L1 ICI immunotherapy as part of two prospective RCTs. All patients except one received tremelimumab and durvalumab, either sequentially or in combination, and one additional patient received ipilimumab and nivolumab. Clinical-pathologic and tumor somatic mutation information (obtained from clinical next-generation sequencing) were correlated with overall survival (OS) using Kaplan-Meier and log-rank methodologies. Conclusions: These preliminary data suggest that PPP2R1A (rather than ARID1A) mutations may serve as a biomarker for long-term survival after ICI in OCCC, and ongoing research is aimed at determining a causal relationship. Given the benefit was delayed and often followed initial progression, harboring PPP2R1A mutations on ICI treatment beyond progression in patients with OCCC may be a consideration after appropriate counseling. Objectives: Response rates to immune checkpoint inhibitors (ICI) in recurrent ovarian cancer have been disappointingly low. While emerging data suggest increased activity in patients with ovarian clear cell carcinomas (OCCC), only a minority of patients benefit even among this group. The objective of the current study was to investigate correlates of long-term survival in patients with OCCC treated with ICI. Methods: A review of medical records identified 28 patients with ovarian/peritoneal clear cell carcinoma who had been treated with CTLA4 and PD1/L1 ICI immunotherapy as part of two prospective RCTs. All patients except one received tremelimumab and durvalumab, either sequentially or in combination, and one additional patient received ipilimumab and nivolumab. Clinical-pathologic and tumor somatic mutation information (obtained from clinical next-generation sequencing) were correlated with overall survival (OS) using Kaplan-Meier and log-rank methodologies. Conclusions: These preliminary data suggest that PPP2R1A (rather than ARID1A) mutations may serve as a biomarker for long-term survival after ICI in OCCC, and ongoing research is aimed at determining a causal relationship. Given the benefit was delayed and often followed initial progression, harboring PPP2R1A mutations on ICI treatment beyond progression in patients with OCCC may be a consideration after appropriate counseling." @default.
• W4295226681 created "2022-09-12" @default.
• W4295226681 creator A5000098403 @default.
• W4295226681 creator A5000158770 @default.
• W4295226681 creator A5001967366 @default.
• W4295226681 creator A5004524112 @default.
• W4295226681 creator A5006094386 @default.
• W4295226681 creator A5008937427 @default.
• W4295226681 creator A5009442045 @default.
• W4295226681 creator A5019407817 @default.
• W4295226681 creator A5021388330 @default.
• W4295226681 creator A5021659252 @default.
• W4295226681 creator A5022433976 @default.
• W4295226681 creator A5026269100 @default.
• W4295226681 creator A5028309981 @default.
• W4295226681 creator A5033798832 @default.
• W4295226681 creator A5045683633 @default.
• W4295226681 creator A5048055401 @default.
• W4295226681 creator A5049857815 @default.
• W4295226681 creator A5057357649 @default.
• W4295226681 creator A5058703108 @default.
• W4295226681 creator A5067136916 @default.
• W4295226681 creator A5076348819 @default.
• W4295226681 creator A5080656521 @default.
• W4295226681 creator A5082358197 @default.
• W4295226681 creator A5090232818 @default.
• W4295226681 date "2022-08-01" @default.
• W4295226681 modified "2023-09-27" @default.
• W4295226681 title "Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099)" @default.
• W4295226681 doi "https://doi.org/10.1016/s0090-8258(22)01325-7" @default.
• W4295226681 hasPublicationYear "2022" @default.
• W4295226681 type Work @default.
• W4295226681 citedByCount "1" @default.
• W4295226681 countsByYear W42952266812022 @default.
• W4295226681 crossrefType "journal-article" @default.
• W4295226681 hasAuthorship W4295226681A5000098403 @default.
• W4295226681 hasAuthorship W4295226681A5000158770 @default.
• W4295226681 hasAuthorship W4295226681A5001967366 @default.
• W4295226681 hasAuthorship W4295226681A5004524112 @default.
• W4295226681 hasAuthorship W4295226681A5006094386 @default.
• W4295226681 hasAuthorship W4295226681A5008937427 @default.
• W4295226681 hasAuthorship W4295226681A5009442045 @default.
• W4295226681 hasAuthorship W4295226681A5019407817 @default.
• W4295226681 hasAuthorship W4295226681A5021388330 @default.
• W4295226681 hasAuthorship W4295226681A5021659252 @default.
• W4295226681 hasAuthorship W4295226681A5022433976 @default.
• W4295226681 hasAuthorship W4295226681A5026269100 @default.
• W4295226681 hasAuthorship W4295226681A5028309981 @default.
• W4295226681 hasAuthorship W4295226681A5033798832 @default.
• W4295226681 hasAuthorship W4295226681A5045683633 @default.
• W4295226681 hasAuthorship W4295226681A5048055401 @default.
• W4295226681 hasAuthorship W4295226681A5049857815 @default.
• W4295226681 hasAuthorship W4295226681A5057357649 @default.
• W4295226681 hasAuthorship W4295226681A5058703108 @default.
• W4295226681 hasAuthorship W4295226681A5067136916 @default.
• W4295226681 hasAuthorship W4295226681A5076348819 @default.
• W4295226681 hasAuthorship W4295226681A5080656521 @default.
• W4295226681 hasAuthorship W4295226681A5082358197 @default.
• W4295226681 hasAuthorship W4295226681A5090232818 @default.
• W4295226681 hasConcept C104317684 @default.
• W4295226681 hasConcept C121608353 @default.
• W4295226681 hasConcept C126322002 @default.
• W4295226681 hasConcept C143998085 @default.
• W4295226681 hasConcept C185592680 @default.
• W4295226681 hasConcept C2777472916 @default.
• W4295226681 hasConcept C2777546739 @default.
• W4295226681 hasConcept C2777701055 @default.
• W4295226681 hasConcept C2778560582 @default.
• W4295226681 hasConcept C2778650287 @default.
• W4295226681 hasConcept C2780030458 @default.
• W4295226681 hasConcept C2780427987 @default.
• W4295226681 hasConcept C2781199814 @default.
• W4295226681 hasConcept C2781273526 @default.
• W4295226681 hasConcept C2781433595 @default.
• W4295226681 hasConcept C501734568 @default.
• W4295226681 hasConcept C55493867 @default.
• W4295226681 hasConcept C71924100 @default.
• W4295226681 hasConceptScore W4295226681C104317684 @default.
• W4295226681 hasConceptScore W4295226681C121608353 @default.
• W4295226681 hasConceptScore W4295226681C126322002 @default.
• W4295226681 hasConceptScore W4295226681C143998085 @default.
• W4295226681 hasConceptScore W4295226681C185592680 @default.
• W4295226681 hasConceptScore W4295226681C2777472916 @default.
• W4295226681 hasConceptScore W4295226681C2777546739 @default.
• W4295226681 hasConceptScore W4295226681C2777701055 @default.
• W4295226681 hasConceptScore W4295226681C2778560582 @default.
• W4295226681 hasConceptScore W4295226681C2778650287 @default.
• W4295226681 hasConceptScore W4295226681C2780030458 @default.
• W4295226681 hasConceptScore W4295226681C2780427987 @default.
• W4295226681 hasConceptScore W4295226681C2781199814 @default.
• W4295226681 hasConceptScore W4295226681C2781273526 @default.
• W4295226681 hasConceptScore W4295226681C2781433595 @default.
• W4295226681 hasConceptScore W4295226681C501734568 @default.
• W4295226681 hasConceptScore W4295226681C55493867 @default.
• W4295226681 hasConceptScore W4295226681C71924100 @default.
• W4295226681 hasLocation W42952266811 @default.
• W4295226681 hasOpenAccess W4295226681 @default.
• W4295226681 hasPrimaryLocation W42952266811 @default.

• next